Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3757 - Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine

Date

09 Sep 2017

Session

Poster display session

Presenters

Richard Riedel

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

R. Riedel1, A. Kron1, S. Michels1, J. Fassunke2, M. Scheffler1, R. Fischer1, L. Nogova1, D. Abdulla1, C. Heydt2, F. Ueckeroth2, B. Pauli1, M. Serke3, S. Krueger4, C. Grohe5, M. Sebastian6, D. Koschel7, K. Kambartel8, T. Zander1, R. Büttner2, J. Wolf1

Author affiliations

  • 1 Department I Of Internal Medicine, Lung Cancer Group Cologne, University Hospital of Cologne, 50937 - Cologne/DE
  • 2 Institute Of Pathology, University Hospital of Cologne, 50937 - Cologne/DE
  • 3 Department Of Pneumology, Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH, 58675 - Hemer/DE
  • 4 Department Of Pneumology, Florence Nightingale-Krankenhaus, Düsseldorf/DE
  • 5 Department Of Pneumology, Evangelische Lungenklinik ELK Berlin Chest Hospital, 13125 - Berlin/DE
  • 6 Department Of Oncology And Haematology, Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), 60590 - Frankfurt am Main/DE
  • 7 Department Of Pneumology, Fachkrankenhaus Coswig, 01640 - Coswig/DE
  • 8 Department Of Pneumology, Bethanien Hospital Moers-Lungenzentrum, 47441 - Moers/DE
More

Resources

Abstract 3757

Background

Anaplastic lymphoma kinase (ALK) gene rearrangements define a molecular subtype of 3-4% of non-small-cell lung cancer (NSCLC), highly sensitive to therapy with ALK-directed tyrosine kinase inhibitors (TKI). Genetic heterogeneity of ALK-positive lung cancer patients (pts) is poorly characterized due to the lack of multiplex diagnostics results besides conventional FISH diagnostics. The Network Genomic Medicine (NGM) performs next generation sequencing (NGS) based diagnostics on a central platform in Cologne for advanced lung cancer pts in Germany.

Methods

The NGS panel used in NGM consists of 17 genes covering potentially targetable aberrations and is run on an Illumina (MySeq) platform. In 2016, we have started retrospective evaluation of ALK-positive NGM pts with available clinical data from the time period before and after NGS implementation. In particular, we have focused on ALK-positive NSCLC pts treated with chemotherapy, crizotinib and next generations TKI. Furthermore, we have analyzed the impact of co-occurring mutations: their frequency, significance and impact on overall survival.

Results

We have analyzed 289 ALK-positive pts with eligible clinical data. Co-occurring mutations were detected in 31% of these pts. The most frequent co-alteration was mutated TP53 in 23% of the ALK-positive patients. Regardless of the treatment regime, pts without co-occurring mutations seem to have a better overall survival (OS) with 37 versus (vs.) 15 month in pts with co-mutations (p = 0.038). TP53 co-mutated pts show an OS of 10 month (p = 0.004). Likewise, next generation TKI treatment exerts a highly positive impact on overall survival compared to chemotherapy and crizotinib treatment: 50 vs. 11 vs. 31 month (p > 0.0001).

Conclusions

While the first NGM evaluation in 2013 already showed a survival benefit of pts with activating genetic aberrations in EGFR and ALK, our current evaluation shows the heterogeneity of ALK-positive lung cancer pts and, for the first time to our knowledge, the impact of co-occurring mutations in these pts cohort. This work provides evidence for the efficacy of sequential ALK inhibitor treatment using next generation inhibitors and underlines the relevance of multiplex genotyping.

Clinical trial identification

Legal entity responsible for the study

University Hospital of Cologne for the Network Genomic Medicine

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.